ESMO 2014 - Immuno-Oncology

Updated OS Data for the CA184-043 Trial: Immunotherapy with Ipilimumab Does Not Improve Survival in Patients with Metastatic Prostate Cancer

Conference Correspondent - ESMO 2014 - Immuno-Oncology

Ipilimumab is an approved immunotherapy that blocks the function of the immune checkpoint modulator CTLA-4 (cytotoxic T-lymphocyte antigen-4) to augment T-cell antitumor immune responses. The multicenter, randomized, double-blind, phase 3 clinical trial CA184-043 evaluated the efficacy of radiotherapy followed by [ Read More ]